Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane

Microvascular Research

Volumn 47, Issue 1, 1994, Pages 31-40

  Nguyen, Mai ^a,b   Shing, Yuen ^a,d   Folkman, Judah ^a,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Anatomy and Cellular Biology ^*  (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0028357885     PISSN: 00262862     EISSN: None     Source Type: Journal    
DOI: 10.1006/mvre.1994.1003     Document Type: Article

References (31)

1. Auerbach, R., Kubai, L., Knighton, D., and Folkman, J. (1974). A simple procedure for the long term cultivation of chicken embryos. Dev. Biol. 41, 391-394.
2. Barnhill, R., and Ryan, T. (1983). Biochemical modulation of angiogenesis in the chorioallantoic membrane of the chick embryo. J. Invest. Dermatol. 81, 485-488.
3. Crum, R., Szabo, S., and Folkman, J. (1985). A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230, 1375-1378.
4. Dusseau, J., Hutchens, P., and Malbasa, D. (1986). Stimulation of angiogenesis by adenosine on the chick chorioallantoic membrane. GVc. Res. 59, 163-170.
5. Ezekowitz, R. A., Mulliken, J. B., and Folkman, J. (1992). Interferon a-2A therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326, 1456-1463.
6. Folkman, J., Hausdenschild, C., and Zetter, B. (1979). Long term culture of capillary en dothelial cells. Proc. Natl. Acad. Sci. USA 76, 5217-5221.
7. Folkman, J., and Klagsbrun, M. (1987). Angiogenic factors. Science 235, 442-447.
8. Folkman, J., Szabo, S., and Shing, Y. (1990). Sucralfate affinity for fibroblast growth factor. J. Cell. Biol. III, 223a.
9. Folkman, J., Szabo, S., Stovroff, M., McNeil, P., Li, W., and Shing, Y. (1991). Duodenal ulcer: Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann. Surg. 214, 414-427.
10. Folkman, J., Weisz, P., Joullie, M., Li, W., and Ewing, W. (1989). Control of angiogenesis with synthetic heparin substitutes. Science 243, 1490-1493.
11. Form, D, and Auerbach, R. (1983). PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 172, 214-218.
12. Gimbrone, M., Cotran, R., and Folkman, J. (1974). Tumor growth neovascularization: An experimental model using rabbit cornea. J. Natl. Cancer Inst. 52, 413-427.
13. Gush, R., Thompson, J., and Weiss, J. (1990). Measurement of blood flow with duck egg yolk sac membrane. J. Med. Eng. Tech. 14, 205-209.
14. Harris-Hooker, S., Gajdusek, C., Wight, T., and Schwartz, S. (1983). Neovascular responses by cultured aortic endothelial cells. J. Celt. Physiol. 114, 302-310.
15. Hori, A., Sasada, R., Matsutani, E., Naito, K., Sakura, Y., Fujita, T., and Kozai, Y. (1991). Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 51, 6180-6184.
16. Ingber, D., Fujita, T., Kishomoto, S., Kanamaku, T., Sudo, K., Brem, H., and Folkman, J. (1990). Angioinhibins: Synthetic analogues of fumagillin which inhibit angiogenesis and suppress tumour growth. Nature 348, 555-557.
17. Jakob, W., and Voss, K. (1984). Utilization of image analysis for the quantification of vascular responses in the chick chorioallantoic membrane. Exp. Pathol. 26, 93-99.
18. Kandel, J., Bossy-Wetzel, E., Radvanyi, F., Klagsbrun, M., Folkman, J., and Hanahan, D. (1991). Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66, 1095-1104.
19. Klagsbrun, M., and Folkman, J. (1990). “Handbook of Experimental Pharmacology,” Vol. 95, pp. 549-586. Springer-Verlag, Berlin.
20. Knighton, D., Ausprunk, D., Tapper, D., and Folkman, J. (1977). Avascular and vascular phases of tumor growth in the chick embryo. Br. J. Cancer 35, 347-356.
21. Shing, Y., Gonzalez, E., Li, W., Casey, R., Panigraphy, D., and Folkman, J. (1992). Production of corneal angiogenesis by a sustained-release implant of basic fibroblast growth factor. A.R.V.O. 33, 1027.
22. Siegel, S. (1956). “Nonparametric Statistics for the Behavioral Sciences,” pp. 116-126. McGraw-Hill, New York.
23. Splawinski, J., Michna, M., Palczak, R., Konturek, S., and Splawinska, B., Angiogenesis: Quantitative assessment by the chick chorioallantoic membrane assay. Methods Find. Expl. Clin. Pharmacol. 10, 221-226.
24. Strjck, D. M., Waycaster, R. L., Montani, J., Gay, W. J., and Adair, T. H. (1991). Mor-phometric measurements of chorioallantoic membrane vascularity: Effects of hypoxia and hype-roxia. Am. J. Physiol. 29, H1385-H1389.
25. Tanaka, N., Sakamoto, N., Tohgo, A., Nishyama, Y., and Ogawa, H. (1986). Inhibitory effects of antiangiogenic agents on neovascularization and growth of the chorioallantoic membrane (CAM): The possibility of a new CAM assay for angiogenesis inhibition. Exp. Pathol. 30, 143-150.
26. Taylor, S., and Folkman, J. (1982). Protamine is an inhibitor of angiogenesis. Nature 297, 307-312.
27. Thompson, W., Campbell, R., and Evans, T. (1985). Fibrin degradation and angiogenesis: Quantitative analysis of the angiogenic responses in the chick chorioallantoic membrane. J. Pathol. 145, 27-37.
28. Vu, M., Smith, C., Burger, P., and Klintworth, G. (1985). Methods in laboratory investigation: An evaluation of methods to quantitate the chick chorioallantoic membrane assay in angiogenesis. Lab. Invest. 53, 499-508.
29. Weidner, N., Semple, J., and Folkman, J. (1991). Tumor angiogenesis correlates with metastasis in invasive breast carcinoma. N. Engl. J. Med. 324, 1-9.
30. Wilks, J. W., Scott, P. S., Vrba, L. K., and Cocuzza, J. M. (1991). Inhibition of angiogenesis with combination treatments of angiostatic steroids and suramin: Int. J. Rad. Biol. 60, 73-77.
31. Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A., Pauly, R. R., Grant, D. S., and Martin, G. R. (1992). A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67, 519-528.